2',3'-dihydro-4,5-dimethoxy-2'-p-toluenesulfonylspiro[isobenzofuran-1(3H),4'(1'H)-isoquinoline]-3-one | 173548-65-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2',3'-dihydro-4,5-dimethoxy-2'-p-toluenesulfonylspiro[isobenzofuran-1(3H),4'(1'H)-isoquinoline]-3-one
• 英文别名: 2',3'-dihydro-4,5-dimethoxy-2'-p-toluenesulfonylspiro[isobenzofuran-1(3H),4'(1'H)isoquinoline]-3-one；2',3'-dihydro-4,5-dimethoxy-2'-(p-tolylsulfonyl)spiro[isobenzofuran-1(3H),4'(1'H)isoquinolin]-3-one；6',7'-Dimethoxy-2-(4-methylphenyl)sulfonylspiro[1,3-dihydroisoquinoline-4,3'-2-benzofuran]-1'-one
• CAS: 173548-65-7
• 化学式: C₂₅H₂₃NO₆S
• 分子量: 465.527
• InChiKey: DSHSEQDQBCYLEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  90.5
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2',3'-dihydro-4,5-dimethoxy-2'-p-toluenesulfonylspiro[isobenzofuran-1(3H),4'(1'H)-isoquinoline]-3-one 在 palladium on activated charcoal disodium hydrogenphosphate 、 sodium amalgam 、 硼烷四氢呋喃络合物 、 硫酸 、 氢气 、 sodium 、 汞 作用下， 以 四氢呋喃 、 甲醇 、 溶剂黄146 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 52.0h， 生成 8,9-Dimethoxy-2,3,7,11b-tetrahydro-1H-naphth[1,2,3-de]isoquinoline
  参考文献：
  名称：

  8,9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline:  A Potent Full Dopamine D₁ Agonist Containing a Rigid β-Phenyldopamine Pharmacophore

  摘要：

  The present work reports the synthesis and preliminary pharmacological characterization of 8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline (4, dinapsoline). This molecule was designed to conserve the essential elements contained in our D-1 agonist pharmacophore model (i.e., position and orientation of the nitrogen, hydroxyls, and phenyl rings). It involved taking the backbone of dihydrexidine [3; (+/-)-trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[alpha]phenanthridine], the first high-affinity full D-1 agonist, and tethering the two phenyl rings of dihydrexidine through a methylene bridge and removing the C(7)-C(8) ethano bridge. Preliminary molecular modeling studies demonstrated that these modifications conserved the essential elements of the hypothesized pharmacopore. Dinapsoline 4 had almost identical affinity (K-I = 5.9 nM) to 3 at rat striatal D-1 receptors and had a shallow competition curve (n(H) = 0.66) that suggested agonist properties. Consistent with this, in both rat striatum and C-6-mD(1) cells, dinapsoline 4 was a full agonist with an EC(50) Of Ca 30 nM in stimulating synthesis of cAMP via D-1 receptors. The design and synthesis of dinapsoline 4 provide a powerful test of the model of the D-1 pharmacophore we have developed and provide another chemical series that can be useful probes for the study of D-1 receptors. An interesting property of 3 is that it also has relatively high D-2 affinity (K-0.5 = 50 nM) despite having an accessory phenyl ring usually thought to convey D-1 selectivity. Dinapsoline 4 was found to have even higher affinity for the D-2 receptor (K-0.5 = 31 nM) than 3. Because of the high affinity of 4 for D-2 receptors, it and its analogs can be powerful tools for exploring the mechanisms of ''functional selectivity'' (i.e., that 3 is an agonist at some D-2 receptors, but an antagonist at others). Together, these data suggest that 4 and its derivatives may be powerful tools in the study of dopamine receptor function and also have potential clinical utility in Parkinson's disease and other conditions where perturbation of dopamine receptors is useful.

  DOI：

  10.1021/jm950707+
• 作为产物：
  描述：

  对甲苯磺酰氯 、 2',3'-dihydro-4,5-dimethoxyspiro[isobenzofuran-1(3H),4'(1'H)-isoquinoline]-3-one hydrochloride 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 1.0h， 以97%的产率得到2',3'-dihydro-4,5-dimethoxy-2'-p-toluenesulfonylspiro[isobenzofuran-1(3H),4'(1'H)-isoquinoline]-3-one
  参考文献：
  名称：

  Co-administration of dopamine-receptor binding compounds

  摘要：

  描述了治疗患有神经、精神和精神障碍的患者的方法，包括向患者施用部分和/或全多巴胺D1受体激动剂的有效量，并向患者施用多巴胺D2受体拮抗剂的有效量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以以相同或不同的组合或组合物形式向患者施用。

  公开号：

  US20070155720A1

文献信息

• Co-administration of dopamine-receptor binding compounds
  申请人：Fernandes B. Prabhavathi

  公开号：US20070155720A1

  公开（公告）日：2007-07-05

  Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D 1 receptor agonist, and administering to the patient an effective amount of a dopamine D 2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D 1 receptor agonist and a dopamine D 2 receptor antagonist are also described. The D 1 dopamine receptor agonist and the D 2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

  描述了治疗患有神经、精神和精神障碍的患者的方法，包括向患者施用部分和/或全多巴胺D1受体激动剂的有效量，并向患者施用多巴胺D2受体拮抗剂的有效量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以以相同或不同的组合或组合物形式向患者施用。
• Method of Administration of Dopamine Receptor Agonists
  申请人：Fernandes B. Prabhavathi

  公开号：US20070254906A1

  公开（公告）日：2007-11-01

  Methods for treating a patient having pulmonary edema are described. The methods include administering to the lung endobronchial space of the airways of the patient an effective amount of a dopamine D 1 receptor agonist. Dopamine D 1 receptor agonists, including hexahydrobenzophenanthridine, hexahydrothienophenanthridine, phenyltetrahydrobenzazepine, chromenoisoquinoline, naphthoisoquinoline dopamine receptor agonists, and their pharmaceutically acceptable salts, formulated as aerosols and dry powders are also described.

  本文描述了治疗肺水肿患者的方法。该方法包括向患者的呼吸道肺内支气管空间内注射有效量的多巴胺D1受体激动剂。本文还介绍了多巴胺D1受体激动剂，包括六氢苯并苯并芳烃、六氢噻吩并芳烃、苯基四氢苯并氮杂环、香豆素异喹啉、萘异喹啉多巴胺受体激动剂及其药学上可接受的盐，制成气溶胶和干粉。
• Co-Administration of Dopamine-Receptor Binding Compounds
  申请人：Fernandes Prabhavathi B.

  公开号：US20100041690A1

  公开（公告）日：2010-02-18

  Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D 1 receptor agonist, and administering to the patient an effective amount of a dopamine D 2 receptor antagonist, Pharmaceutical compositions comprising a dopamine D 1 receptor agonist and a dopamine D 2 receptor antagonist are also described. The D 1 dopamine receptor agonist and the D 2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

  描述了治疗神经、精神和精神障碍患者的方法，包括向患者施用部分和/或完全的多巴胺D1受体激动剂的有效剂量，并向患者施用多巴胺D2受体拮抗剂的有效剂量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以在同一组合物或不同组合物中向患者施用。
• [EN] METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS<br/>[FR] PROCEDES D'ADMINISTRATION D'AGONISTES DU RECEPTEUR DE LA DOPAMINE
  申请人：DARPHARMA INC

  公开号：WO2006012640A3

  公开（公告）日：2009-04-16
• US6194423B1
  申请人：——

  公开号：US6194423B1

  公开（公告）日：2001-02-27